glp-1 reactive hypoglycemia Hypoglycemia: Avoiding the Blood Sugar Crash hypoglycemia and glp-1 Relative effects

In Phase 1 and 2a clinical trials, once-daily subcutaneous injections of RG7697 (0.252.5 mg) for 14 days in 56 patients with T2DM and 1.8 mg of RG7697 for 12 weeks in patients with T2DM who were poorly responsive to metformin reduced body weight and improved glycemic control

PMID: 12718765

Kalmbacher for personalized advice

Severe vomiting or dehydration can worsen kidney function, particularly in people who already have kidney disease

This means that a peptide with a 2-hour half-life administered three times daily will reach steady-state within approximately 10 hours, while a peptide with a 7-day half-life like Semaglutide requires roughly 35 days to reach steady state with weekly dosing